List/Grid Tag Archives: ANR 2010

Antibodies and other bits

Big antibody news The “third generation” humanized anti-GD2 antibody with protein fusion of IL2 to the antibody has completed Phase I and II clinical trials for melanoma and neuroblastoma, and is now ready for use in Phase III clinical trials. The license for hu14.18-IL2 was just acquired by a small biotech in Vienna called Apeiron. The license was acquired from Merck. Apeiron’s press ...

SIOP 2010 ~ Neuroblastoma oral paper presented on poor prognostic features

The neuroblastoma oral papers (OP2) presented on Friday October 22, 2010 at SIOP in Boston covered a range of topics including prognostic factors, targets, and stem cell contamination. This report will focus on the presentation on prognostic significance of segmental alterations in neuroblastoma tumors. Accumulation of segmental alterations determines progression in neuroblastoma (O024) Neuroblastoma ...

Guest Report: ANR 2010 Advances in Neuroblastoma Research

Report from Stockholm by John Rogers, PhD The following report was prepared by Dr John Rogers after attending the ANR meeting. He is a physicist at the University of Kent, near Canterbury in the UK. His daughter recently finished frontline NB therapy in the UK and the ch14.18 study at Children’s Hospital of Philadelphia. Many thanks go to John for permission to share his keen insights from this ...

New frontline high-risk neuroblastoma trial includes MIBG transplant

Pilot study: 131I-MIBG radiotherapy with chemotherapy after induction for newly diagnosed Dr Greg Yanik (University of Michigan) presented preliminary results of the NANT (New Approaches to Neuroblastoma Therapy) NANT-2001-02 phase 2 MIBG + CEM (131I-MIBG radiotherapy with carboplatin, etoposide, and melphalan) stem cell transplant trial on June 23rd 2010 at the Advances in Neuroblastoma Research ...

ANR 2010 ~ Late Effects of Neuroblastoma Treatment

C10 (p. 80) “Late effects in neuroblastoma” Dr Lisa Diller (Boston Children’s/Dana-Farber Cancer Institute) reviewed recent published data on late effects and presented new data in the Neuroblastoma Update Course on June 21st, 2010 at the Advances in Neuroblastoma Research meeting in Stockholm, Sweden. The session was organized by Sue Cohn and Andrew Pearson and chaired by Sue Cohn ...

ANR 2010 ~ Treating neuroblastoma relapse with high dose MIBG and haploidentical stem cell transplant in Sweden

SEL11 (p 136) “High dose MIBG and haploidentical stem cell transplantation with cell therapy in therapy resistant neuroblastoma” Janek Toporski presented (5 minutes) for the Swedish group in the “Clinical” session for selected posters at ANR Tuesday June 22 . This was a very small study with only 10 patients. The purpose was to evaluate the feasibility of high dose MIBG radiation ...

ASCO 2010 & ANR 2010 ~ Survival after neuroblastoma relapse

Clinical and biological features predictive of survival after relapse of neuroblastoma: A study from the International Neuroblastoma Risk Group (INRG) Database. Citation: J Clin Oncol 28:15s, 2010 (suppl; abstr 9518) Wendy London is the Lead Statistician for neuroblastoma research for the Children’s Oncology Group (COG), and Data Center Statistics Committee Chair for the International Neuroblastoma ...

ANR 2010 ~ UK group reports on long-term survival with persistent neuroblastoma

SEL 10 (p. 136) “Persistence of disease in long-term survivors of high-risk neuroblastoma. Analysis of ENSG5 cooperative trial” Presented by Lucas Moreno of UK A report on long-term survivors of high-risk neuroblastoma with persistent (refractory) disease was presented at ANR by Lucas Moreno on Tuesday as one of the selected posters in the clinical session. This is the first time persistence ...

ANR 2010: MIBG avidity, tandem transplant (Korea), and ch14.18 (Germany) updates

MIBG non-avid at diagnosis = better outcome? POC39 (p. 211) Neuroblastomas with non-avid I-123 MIBG scan and negative urinary catecholamine secretion: A single institute’s experience PL30 (p. 102) Analysis of MIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma. A Children’s Oncology Group (A3973) report Dui Yen Soh, Sylvain Baruchel, and Meredith Irwin at Sick Kids in ...

ANR 2010: International Neuroblastoma Risk Group (INRG) Update

In 1988 an international task force was formed to standardize the risk group classification for neuroblastoma. The reason this is so important is because international studies could not be compared to each other with different patient cohorts. One “high risk” study might actually include children considered to be intermediate risk by another group, and the outcomes reported may consequently ...
© 2014 NB Globe ~ Neuroblastoma News. All rights reserved. | Contact Us